InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (30 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
30
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Anzalone Christopher Richard, Chief Executive Officer. Director active across 2 companies, notably Arrowhead Pharmaceuticals, INC.. Aggregated, 50 disclosures have been published. Breakdown: 0 buy · 30 sells. Total volume traded: €22.4m. History available since 20 October 2021. The latest transaction was filed on 2 January 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Anzalone Christopher Richard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations50 total
7,416 shares@ US$65.880.0039% mcap3.4% of flowCommon StockSEC:0001423029-26-000001:0
35,181 shares@ US$6.150.0017% mcap1.5% of flowCommon StockSEC:0001423029-25-000009:0
16,545 shares@ US$6.150.3% of flowCommon StockSEC:0001423029-25-000009:1
35,181 shares@ US$69.336.3% of flowCommon StockSEC:0001423029-25-000009:2
16,545 shares@ US$68.692.9% of flowCommon StockSEC:0001423029-25-000009:3
3,979 shares@ US$66.670.0021% mcap1.8% of flowCommon StockSEC:0001423029-25-000007:0
8,147 shares@ US$68.011.4% of flowCommon StockSEC:0001423029-25-000007:1
1,319 shares@ US$68.480.2% of flowCommon StockSEC:0001423029-25-000007:2
10,012 shares@ US$68.331.8% of flowCommon StockSEC:0001423029-25-000007:3
2,574 shares@ US$68.850.5% of flowCommon StockSEC:0001423029-25-000007:4
46,287 shares@ US$63.550.023% mcap20.4% of flowCommon StockSEC:0001423029-25-000005:0
180,000 shares0Common StockSEC:0001423029-25-000003:0
100,532 shares@ US$68.6717.8% of flowCommon StockSEC:0001423029-25-000003:1
21,321 shares@ US$69.283.8% of flowCommon StockSEC:0001423029-25-000003:2
8,147 shares@ US$69.961.5% of flowCommon StockSEC:0001423029-25-000003:3
8,416 shares@ US$60.511.3% of flowCommon StockSEC:0001423029-25-000003:4
10,963 shares@ US$61.251.7% of flowCommon StockSEC:0001423029-25-000003:5
14,095 shares@ US$62.122.3% of flowCommon StockSEC:0001423029-25-000003:6
8,476 shares@ US$62.941.4% of flowCommon StockSEC:0001423029-25-000003:7
6,661 shares@ US$64.291.1% of flowCommon StockSEC:0001423029-25-000003:8
1,000 shares@ US$64.960.2% of flowCommon StockSEC:0001423029-25-000003:9
1,300 shares@ US$65.770.2% of flowCommon StockSEC:0001423029-25-000003:10
166 shares@ US$66.770.0% of flowCommon StockSEC:0001423029-25-000003:11
3,221 shares@ US$67.870.6% of flowCommon StockSEC:0001423029-25-000003:12
35,305 shares@ US$9.931.0% of flowCommon StockSEC:0001628280-25-017592:0
25 of 50 declarations
About Anzalone Christopher Richard
Anzalone Christopher Richard is Chief Executive Officer at Arrowhead Pharmaceuticals, INC. and ARROWHEAD RESEARCH CORP. He has made 50 filings in total, and across the 50 recent filings sampled, they show EUR 22,372,625 of sales between 2016-01-04 and 2026-01-05.
